According to the WHO, obesity is an epidemic that kills at least 2.8 million people each year. The number of obese children and adolescents worldwide has risen tenfold in the past four decades. Obesity is a major risk factor for heart disease, stroke, osteoarthritis, diabetes, liver disease such as non-alcoholic steatohepatitis (NASH), and certain cancers. Muscular dystrophies, such as Duchenne, myotonic and facioscapulohumeral currently have no cure.
Staging and progression of these conditions can be measured by the amount of muscle tissue that has been replaced by fat. As pharmaceutical companies attempt to develop treatments for noncommunicable, obesity-related diseases and muscular dystrophies, it is important to monitor body composition as both an efficacy and safety endpoint. The traditional body composition measurement has been BMI. While BMI provides a rough estimate of how over- or underweight a person is, it does not distinguish how much weight comes from muscle, how much comes from fat and how these tissues are affected by the treatment.
BioTel Research’s Vice President of Musculoskeletal and Metabolic Imaging, Jonathan Riek, PhD, and AMRA’s Chief Scientific Officer and Co-Founder, Olof Dahlqvist Leinhard, PhD, presented an education webinar entitled: Body Composition in Clinical Trials – From BMI to MRI. This webinar discussed alternative, noninvasive imaging methods to determine body composition. Including, how imaging methods range from the most simplistic thickness measurements from ultrasound, to the more advanced measurements of fat distribution, muscle tissue, and diffuse infiltration of fat in muscle and liver tissue from DXA, CT and MRI.
Key topics include:
Advantages of noninvasive imaging methods
When to use ultrasound, DXA, CT and MRI to measure body composition and how to successfully implement these modalities in clinical trials
Body composition measurements from rapid, highly standardized, whole-body MRI
Did you miss the webinar? Don't worry you can now view it on-demand!